Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LESLIE BRYAN FORGOSH

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1154305738
CMS profile
278624
Location
SAINT PAUL, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,534.72

16 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $2,008.34 8
Food and Beverage $526.38 8

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Bayer Healthcare Pharmaceuticals Inc. $1,377.65 9
Merck Sharp & Dohme LLC $1,157.07 7

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LESLIE BRYAN FORGOSH

NPI 1154305738 · CMS profile ID 278624

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

SAINT PAUL, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1154305738?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LESLIE BRYAN FORGOSH, NPI 1154305738, CMS profile ID 278624. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154305738?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). LESLIE BRYAN FORGOSH, NPI 1154305738, CMS profile ID 278624. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154305738?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
LESLIE BRYAN FORGOSH, NPI 1154305738, CMS profile ID 278624, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1154305738?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

16 matching records · $2,534.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 16 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–16 of 16.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $75.0008/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048405745 CMS
Merck Sharp & Dohme LLC $57.9908/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048405857 CMS
Merck Sharp & Dohme LLC $515.5508/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048405863 CMS
Merck Sharp & Dohme LLC $40.0008/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048764791 CMS
Merck Sharp & Dohme LLC $174.8508/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048405859 CMS
Merck Sharp & Dohme LLC $196.7208/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048405861 CMS
Merck Sharp & Dohme LLC $96.9608/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048764787 CMS
Bayer Healthcare Pharmaceuticals Inc. $34.2804/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000421345 CMS
Bayer Healthcare Pharmaceuticals Inc. $34.2804/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000421353 CMS
Bayer Healthcare Pharmaceuticals Inc. $75.4204/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000422687 CMS
Bayer Healthcare Pharmaceuticals Inc. $84.4204/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000423081 CMS
Bayer Healthcare Pharmaceuticals Inc. $116.8404/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000424107 CMS
Bayer Healthcare Pharmaceuticals Inc. $78.6704/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000422933 CMS
Bayer Healthcare Pharmaceuticals Inc. $124.9904/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000424777 CMS
Bayer Healthcare Pharmaceuticals Inc. $210.9004/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000425945 CMS
Bayer Healthcare Pharmaceuticals Inc. $617.8504/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000426723 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $37.62 2
PY2020 $13.55 1
PY2022 $3,264.08 18
PY2023 $2,534.72 16
PY2024 $1,618.47 10
PY2025 $1,013.54 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,031.09 11
PY2025 Principal investigator $1,145,528.44 27
PY2024 Principal investigator $1,362,432.04 31
PY2023 Recipient $140.82 1
PY2023 Principal investigator $1,104,464.55 33
PY2022 Recipient $3,197.00 1
PY2022 Principal investigator $739,768.96 53
PY2021 Recipient $4,441.01 1
PY2021 Principal investigator $667,326.41 59
PY2020 Recipient $6,717.97 2
PY2020 Principal investigator $475,435.63 71
PY2019 Principal investigator $661,892.22 89

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

89 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $9,200.00 12/24/2019 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
VESALIUS-CV No dispute reported 06/30/2026 675778469
Principal investigator 1 Amgen Inc. $1,310.00 12/24/2019 Covered Recipient Teaching Hospital
HEALTHEAST ST JOSEPHS HOSPITAL
FOURIER OLE (Ph 4) No dispute reported 06/30/2026 675780033
Principal investigator 1 Aegerion Pharmaceuticals, Inc. $2,500.00 12/18/2019 Non-covered Recipient Entity
Health East Medical Research Institute
Lomitapide Peri & Post No dispute reported 06/30/2026 701458135
Principal investigator 1 Aegerion Pharmaceuticals, Inc. $2,500.00 12/18/2019 Non-covered Recipient Entity
Health East Medical Research Institute
Lomitapide Peri & Post No dispute reported 06/30/2026 701458137
Principal investigator 1 Kowa Research Institute, Inc. $4,402.80 12/17/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 629129269
Principal investigator 1 AKEBIA THERAPEUTICS INC $829.00 12/13/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153325
Principal investigator 1 AKEBIA THERAPEUTICS INC $708.00 12/13/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153327
Principal investigator 1 AKEBIA THERAPEUTICS INC $5,000.00 12/12/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0014 No dispute reported 06/30/2026 707153317
Principal investigator 1 AKEBIA THERAPEUTICS INC $500.00 12/12/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153319
Principal investigator 1 AKEBIA THERAPEUTICS INC $500.00 12/12/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0014 No dispute reported 06/30/2026 707153321
Principal investigator 1 AKEBIA THERAPEUTICS INC $500.00 12/12/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153323
Principal investigator 1 AKEBIA THERAPEUTICS INC $102.00 12/10/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153289
Principal investigator 1 AKEBIA THERAPEUTICS INC $253.00 12/10/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153291
Principal investigator 1 AKEBIA THERAPEUTICS INC $102.00 12/10/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153293
Principal investigator 1 AKEBIA THERAPEUTICS INC $102.00 12/10/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153295
Principal investigator 1 AKEBIA THERAPEUTICS INC $102.00 12/10/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153297
Principal investigator 1 AKEBIA THERAPEUTICS INC $68.00 12/10/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153299
Principal investigator 1 AKEBIA THERAPEUTICS INC $190.00 12/10/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153301
Principal investigator 1 AKEBIA THERAPEUTICS INC $172.00 12/10/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153303
Principal investigator 1 AKEBIA THERAPEUTICS INC $165.00 12/10/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153305
Principal investigator 1 AKEBIA THERAPEUTICS INC $165.00 12/10/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153307
Principal investigator 1 AKEBIA THERAPEUTICS INC $165.00 12/10/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153309
Principal investigator 1 AKEBIA THERAPEUTICS INC $165.00 12/10/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153311
Principal investigator 1 AKEBIA THERAPEUTICS INC $131.00 12/10/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153313
Principal investigator 1 AKEBIA THERAPEUTICS INC $127.00 12/10/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153315
Principal investigator 1 AKEBIA THERAPEUTICS INC $804.00 12/03/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153281
Principal investigator 1 AKEBIA THERAPEUTICS INC $708.00 12/03/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153283
Principal investigator 1 AKEBIA THERAPEUTICS INC $708.00 12/03/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153285
Principal investigator 1 AKEBIA THERAPEUTICS INC $708.00 12/03/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153287
Principal investigator 1 Amgen Inc. $2,375.00 11/27/2019 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
VESALIUS-CV No dispute reported 06/30/2026 675785923
Principal investigator 1 SANOFI US SERVICES INC. $1,341.00 11/25/2019 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 691597869
Principal investigator 1 Kowa Research Institute, Inc. $8,789.40 11/22/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 629129267
Principal investigator 1 Kowa Research Institute, Inc. $4,867.20 10/25/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 629129265
Principal investigator 1 Amgen Inc. $14,587.84 10/11/2019 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
VESALIUS-CV No dispute reported 06/30/2026 675785927
Principal investigator 1 SANOFI US SERVICES INC. $3,349.00 10/09/2019 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 691588395
Principal investigator 1 AKEBIA THERAPEUTICS INC $707.00 10/01/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153267
Principal investigator 1 AKEBIA THERAPEUTICS INC $707.00 10/01/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153269
Principal investigator 1 AKEBIA THERAPEUTICS INC $674.00 10/01/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153271
Principal investigator 1 AKEBIA THERAPEUTICS INC $674.00 10/01/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153273
Principal investigator 1 AKEBIA THERAPEUTICS INC $674.00 10/01/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153275
Principal investigator 1 AKEBIA THERAPEUTICS INC $674.00 10/01/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153277
Principal investigator 1 AKEBIA THERAPEUTICS INC $674.00 10/01/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153279
Principal investigator 1 Kowa Research Institute, Inc. $15,294.60 10/01/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 629129263
Principal investigator 1 Amgen Inc. $2,520.00 09/23/2019 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
VESALIUS-CV No dispute reported 06/30/2026 675785925
Principal investigator 1 Merck Sharp & Dohme Corporation $191.40 08/28/2019 Covered Recipient Teaching Hospital
HEALTHEAST ST JOSEPHS HOSPITAL
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA No dispute reported 06/30/2026 691400255
Principal investigator 1 SANOFI US SERVICES INC. $1,552.00 08/28/2019 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 691590377
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,350.00 07/30/2019 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
PROSPECTIVE COMPARISON OF ARNI WITH ARB GIVEN FOLLOWING STABILIZATION IN DECOMPENSATED HFPEF (PARAGLIDE-HFPEF) No dispute reported 06/30/2026 640717119
Principal investigator 1 SANOFI US SERVICES INC. $2,430.00 07/29/2019 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 691582783
Principal investigator 1 AKEBIA THERAPEUTICS INC $707.00 07/22/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153261
Principal investigator 1 AKEBIA THERAPEUTICS INC $674.00 07/22/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153263
Principal investigator 1 AKEBIA THERAPEUTICS INC $674.00 07/22/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153265
Principal investigator 1 SANOFI US SERVICES INC. $1,936.00 07/22/2019 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 691592507
Principal investigator 1 Merck Sharp & Dohme Corporation $1,214.20 07/19/2019 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA No dispute reported 06/30/2026 709106565
Principal investigator 1 Kowa Research Institute, Inc. $12,162.60 07/18/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 629129261
Principal investigator 1 AKEBIA THERAPEUTICS INC $4,524.00 07/01/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0014 No dispute reported 06/30/2026 707153253
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,000.00 07/01/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0014 No dispute reported 06/30/2026 707153255
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,000.00 07/01/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0014 No dispute reported 06/30/2026 707153257
Principal investigator 1 AKEBIA THERAPEUTICS INC $4,524.00 07/01/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0014 No dispute reported 06/30/2026 707153259
Principal investigator 1 Kowa Research Institute, Inc. $500.00 06/21/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 629129259
Principal investigator 1 AstraZeneca Pharmaceuticals LP $43,722.12 06/20/2019 Non-covered Recipient Entity
Healtheast Medical Research Institute
An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) No dispute reported 06/30/2026 684981849
Principal investigator 1 SANOFI US SERVICES INC. $1,850.00 06/10/2019 Non-covered Recipient Entity
Health East Woodbury Clinic
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular No dispute reported 06/30/2026 691582659
Principal investigator 1 SANOFI US SERVICES INC. $6,884.00 05/29/2019 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 691604891
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,900.00 05/23/2019 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
A MULTICENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP ACTIVE CONTROLLED 8 WEEK STUDY TO EVALUATE THE EFFECT OF LCZ696 VERSUS ENALAPRIL ON CHANGES IN NT PROBNP AND SAFETY AND TOLERABILITY OF IN HOSPITAL INITIATION OF LCZ696 COMPARED TO ENALAPRIL IN HFREF PA No dispute reported 06/30/2026 640717123
Principal investigator 1 Kowa Research Institute, Inc. $4,257.90 05/22/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 629129255
Principal investigator 1 Merck Sharp & Dohme Corporation $750.00 05/08/2019 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA No dispute reported 06/30/2026 691315325
Principal investigator 1 AKEBIA THERAPEUTICS INC $707.00 05/06/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153249
Principal investigator 1 AKEBIA THERAPEUTICS INC $674.00 05/06/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153251
Principal investigator 1 Kowa Research Institute, Inc. $24,075.90 05/06/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 629129257
Principal investigator 1 Amgen Inc. $138,684.00 05/03/2019 Covered Recipient Teaching Hospital
HEALTHEAST ST JOSEPHS HOSPITAL
FOURIER OLE (Ph 4) No dispute reported 06/30/2026 675780037
Principal investigator 1 Merck Sharp & Dohme Corporation $191.40 04/26/2019 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA No dispute reported 06/30/2026 691315273
Principal investigator 1 SANOFI US SERVICES INC. $7,030.00 04/08/2019 Non-covered Recipient Entity
Healtheast Downtown Clinic
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular No dispute reported 06/30/2026 691580597
Principal investigator 1 GlaxoSmithKline, LLC. $5,895.00 03/01/2019 Non-covered Recipient Entity
HEALTHEAST MEDICAL RES INSTITUTE
A LONG TERM, RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO DET No dispute reported 06/30/2026 669961453
Principal investigator 1 Merck Sharp & Dohme Corporation $730.60 02/25/2019 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA No dispute reported 06/30/2026 691326293
Principal investigator 1 GlaxoSmithKline, LLC. $12,464.38 02/14/2019 Non-covered Recipient Entity
HEALTHEAST MEDICAL RES INSTITUTE
A LONG TERM, RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO DET No dispute reported 06/30/2026 669957025
Principal investigator 1 Amgen Inc. $132,283.20 02/11/2019 Covered Recipient Teaching Hospital
HEALTHEAST ST JOSEPHS HOSPITAL
FOURIER OLE (Ph 4) No dispute reported 06/30/2026 675780035
Principal investigator 1 Kowa Research Institute, Inc. $5,736.60 02/07/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 629129251
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 02/01/2019 Non-covered Recipient Entity
HEALTHEAST MEDICAL RES INSTITUTE
A LONG TERM, RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO DET No dispute reported 06/30/2026 669956475
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,179.60 01/31/2019 Covered Recipient Teaching Hospital
HEALTHEAST ST JOSEPHS HOSPITAL
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED EVENT DRIVEN TRIAL OF QUARTERLY SUBCUTANEOUS CANAKINUMAB IN THE PREVENTION OF RECURRENT CARDIOVASCULAR EVENTS AMONG STABLE POST MYOCARDIAL INFARCTION PATIENTS WITH ELEVATED HSCRP No dispute reported 06/30/2026 640706125
Principal investigator 1 Merck Sharp & Dohme Corporation $869.80 01/30/2019 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA No dispute reported 06/30/2026 691307081
Principal investigator 1 AKEBIA THERAPEUTICS INC $972.42 01/28/2019 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153245
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,434.05 01/28/2019 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153247
Principal investigator 1 Amgen Inc. $37,510.00 01/26/2019 Covered Recipient Teaching Hospital
HEALTHEAST ST JOSEPHS HOSPITAL
FOURIER OLE (Ph 4) No dispute reported 06/30/2026 675780031
Principal investigator 1 Kowa Research Institute, Inc. $7,015.50 01/21/2019 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 629129253
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,364.93 01/21/2019 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
A MULTICENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LCZ696 COMPARED TO VALSARTAN ON MORBIDITY AND MORTALITY IN HEART FAILURE PATIENTS NYHA CLASS II TO IV WITH PRESERVED EJECTION FRACTION No dispute reported 06/30/2026 640717125
Principal investigator 1 SANOFI US SERVICES INC. $18,054.00 01/21/2019 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular No dispute reported 06/30/2026 691573169
Principal investigator 1 SANOFI US SERVICES INC. $500.00 01/21/2019 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular No dispute reported 06/30/2026 691573183
Principal investigator 1 SANOFI US SERVICES INC. $8,109.00 01/21/2019 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular No dispute reported 06/30/2026 691573189
Principal investigator 1 AKEBIA THERAPEUTICS INC $159.00 01/16/2019 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 707153243
Principal investigator 1 AstraZeneca Pharmaceuticals LP $36,153.78 01/15/2019 Non-covered Recipient Entity
Healtheast Medical Research Institute
A Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death Myocardial Infarction or Stroke in Patients with Type 2 Diabetes No dispute reported 06/30/2026 684981845